http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
5-fluorouracil 이 근간이 된 화학요법에 실패한 진행성 위암에서 Docetaxel 과 Cisplatin 복합화학요법
이효락(Hyo Rak Lee),박세훈(Se Hoon Park),송서영(Seo Young Song),박준오(Joon Oh Park),이순일(Soon Il Lee),김기현(Ki Hyun Kim),김원석(Won Seog Kim),정철원(Chul Won Jung),임영혁(Young Hyuck Im),이홍기(Hong Ghi Lee),박근칠(Keun Chil Park 대한내과학회 2002 대한내과학회지 Vol.62 No.1
Background: There is no effective treatment in patients with advanced gastric cancer failed to first-line chemotherapy. Taxane is one of new drugs identified as having substantial activity in gastric cancer. We performed a phase II trial to evaluate the efficacy and toxicity of docetaxel plus cisplatin regimen as a salvage chemotherapy for advanced gastric cancer failed to 5-fluorouracil (5-FU)-based chemotherapy. Methods: Metastatic or recurrent gastric cancer patients failed to 5-FU-based regimen with an Eastern Cooperative Oncology Group (ECOG) performance score≤2 were eligible in this trial. Docetaxel (60mg/㎡) was infused over 1 hour , before cisplatin (60 mg/㎡) infused over 2 hours on day 1, once every 3 weeks until disease progression or unacceptable toxicity was detected. Response to treatment was assessed every two or three cycles. Results: From October 1999 to December 2000, forty-one patients were enrolled in this study. Twenty-eight of forty-one patients were assessable for response. Partial response was observed in seven patients and stable disease in four patients. The response rate was 25.0% (95% confidence interval: 20.4-29.6%) and median duration of response was 22 weeks (range: 11-53 weeks). The median survival of all enrolled patients was 24 weeks (range: 7-65 weeks). For a total of 112 cycles of chemotherapy, grade 3 and 4 toxicity was 8.9% for neutropenia, 4.5% for nausea/vomiting and 1.8% for mucositis. Conclusion: Salvage chemotherapy with docetaxel plus cisplatin regimen in gastric cancer was active with acceptable toxicities. (Korean J Med 62:83-89, 2002)
항암치료를 받은 소세포폐암 환자에서 폐포 출혈을 동반한 폐 분선충 감염
김윤정 ( Yoon Jung Kim ),안명주 ( Myung Ju Ahn ),박근칠 ( Keun Chil Park ),이희영 ( Hui Young Lee ),김경희 ( Kyung Hee Kim ),변경민 ( Kyung Min Byeon ),한혜진 ( Hye Jin Han ) 대한내과학회 2009 대한내과학회지 Vol.76 No.4
Strongyloides stercoralis is an intestinal nematode that infects a large portion of the world`s population, especially in tropical areas and other hot, humid regions. In immunocompromised patients, the parasite is augmented by autoinfection, resulting in hyper-infection or systemic dissemination. Pulmonary hemorrhage is a rare presentation of Strongyloides hyperinfection. We experienced a case of Strongyloides hyperinfection with alveolar hemorrhage in an immunocompromised patient. A 63-year-old man with small cell lung carcinoma on chemotherapy presented with abdominal pain and dyspnea. He developed a pulmonary hemorrhage and migrating pneumonia 1 week later, and bronchoalveolar lavage cytology revealed helminthic larvae identified as Strongyloides. The patient received albendazole therapy for 6 weeks, and the Strongyloides hyperinfection and pneumonia were resolved. (Korean J Med 76:502-505, 2009)
비호지킨 림프종에 대한 CHOP 및 CHOP / IMVP - 16 복합화학요법의 치료 효과
강원기(Won Ki Kang),윤성수(Sung Soo Yoon),신동복(Dong Bok Shin),강윤구(Yoon Koo Kang),박근칠(Keun Chil Park),방영주(Yung Jue Bang),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim) 대한내과학회 1989 대한내과학회지 Vol.36 No.3
N/A The authors compared retrospectively two regimens, CHOP and CHOP/IMVP-16 for the patients with intermediate and high grade non-Hodgkin's lymphoma. Between September 1982 and May 1984, 48 patients were treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP), and between June 1984 and November 1986, 70 patients were treated with alternating chemotherapy with CHOP and ifosfamide, methotrexate, and VP-16 (CHOP/IMVP-16). Median age was 42 (range 20-64) in CHOP group and 50 (range 16-74) in CHOP/IMVP-16 group and M:F ratio was 42:6 and 50:20 in each group respectively. No patients had received any previous cytotoxic chemotherapy. The most common histologic types were diffuse histiocytic (DH) and diffuse poorly differentiated lymphocytic (DPDL) with DH 36/48 (75%) and DPDL 6/48 (12.4%) in CHOP group, and DH 50/70 (71.4%) and DPDL 15/70 (21.4%) in CHOP/IMVP-16 group. CHOP consisted of cyclophosphamide 1 g/㎡ 4, day 1; adriamycin 40 ㎎/㎡ 4, day 1; vincristine 2 ㎎/m 4, day 1&8; and predrisone 60 ㎎ PO, day 1-10. And IMVP-16 consisted of ifosfamide 1 g/㎡ 4, day 1-5; methotrexate 30 ㎎/㎡ 4, day 3&10; and VP-16 100 ㎎/㎡ 4, day 1-3. Courses were repeated every 3 weeks. In CHOP/IMVP-16 group, CHOP and IMVP-16 were given alternatingly. Treatment was continued until the disease progression or complete remission (CR), for a total of minimum of 6 cycles. Responses were CR 25/48 (52%) and PR 17/48 (35%) in CHOP group and CR 38/70 (54%) and PR 22/70 (31%) in CHOP/IMVP-16 group. Median duration of response in complete responders was 17.7 months (range 3.0-77+) in CHOP, and 18.4 months (range 2.2+~48.3+) in CHOP/IMVP-16 group. And, in complete responders, 3-year disease-free survival rate is 32.5% and 39.2% in CHOP group and CHOP/IMVP-16 group respectively. Median survival time was 17.5 months (range 3.4~80.4+) in CHOP group and 22.7 months (range 1~51+) in CHOP/IMVP-16 group. There was no statistically significant difference between CHOP and CHOP/IMVP-16 groups.
임영혁(Young Hyuk Im),이제환(Je Hwan Lee),정경해(Kyung Hae Jung),강윤구(Yoon Koo Kang),박근칠(Keun Chil Park),신동복(Dong Bok Shin),이재훈(Jae Hoon Lee),허대석(Dae Seog Heo),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe K 대한내과학회 1990 대한내과학회지 Vol.39 No.4
N/A Twenty-one previously untreated patients with acute lymnocytic leukemia were treated with induction chemotherapy consisting of vincristine, prednisolone, daunorubicin, and L-asparaginase. After sucessful remission induction, CNS prophylaxis was performed with cranial irradiation and intrathecal methotrexate, and alternating chemotherapy with non-cross-resistnat agents was used in consolidation therapy. The results were as follows; 1) Fifteen out of 18 (83.3%) cases achieved complete remission, and the median duration of remission was 26.8 weeks (4-111+weeks). 2) The overall median survival of the patients was 24.8 weeks (2-120+ weeks). 3) The median survival of the responders was longer than that of the nonresponders (38 weeks vs four weeks). 4) The only favorable factor influencing the remission rate was age below 20 years (p<0.05), and the favorable prognostic factor for remission duration was time to remission (<four weeks). 5) Sevent out of 15 (47%) patients in remission suffered relapse, and the sites of relapse were the bone marrow and central nervous system. 6) Non-hematologic toxicities during induction chemotherapy were hepatotoxicity (such as jaundice, elevation of hepatic enzymes, and glucose intolerance), mainly due to L-asparaginase: hematologic toxicities were tolerable. In conclusion, this induction regimen was useful in terms of remission rate, however, it was thought to be ineffective because of the considerable number of side effects and the shortness of the remission duration.